Paul Anders Sletten Olsen

• Donati, Thierry G; Agbariah, Andrea; Benz, Dominik C; Hebeisen, Monika; Saguner, Ardan M & Duru, Firat [Show all 20 contributors for this article] (2026). Tricuspid regurgitation and outcomes in arrhythmogenic right ventricular cardiomyopathy: role of tricuspid annulus dilatation. European Heart Journal. ISSN 0195-668X. doi: 10.1093/eurheartj/ehag694. Full text in Research Archive
• Olsen, Paul Anders Sletten; Leren, Ida Skrinde; Lie, Øyvind Haugen; Bugge, Cecilie; Beitnes, Jan Otto & Berge, Knut Erik [Show all 8 contributors for this article] (2026). Cardiac function and the effect of heart failure treatment in patients with genotype-positive dilated cardiomyopathy. JACC. Heart failure. ISSN 2213-1779. p. 103367–103367. doi: 10.1016/j.jchf.2026.103367. Full text in Research Archive
• Donati, Thierry G.; Ortelli, Francesca; Hebeisen, Monika; Protonotarios, Alexandros; Olsen, Paul Anders Sletten & Saguner, Ardan M. [Show all 11 contributors for this article] (2025). Right Ventricular Outflow Tract Diameter for Event Prediction in Arrhythmogenic Right Ventricular Cardiomyopathy: Incremental Value Over Echocardiographic Free-Wall Strain. JACC Cardiovascular Imaging. ISSN 1936-878X. doi: 10.1016/j.jcmg.2025.10.019. Full text in Research Archive
• Aaserud, Linda Soon Ah Tangen; Rootwelt-Norberg, Christine; Olsen, Paul Anders Sletten; Five, Christian K.; Castrini, Anna Isotta & Aabel, Eivind Westrum [Show all 8 contributors for this article] (2025). Disease Progression in Exercise-Induced Arrhythmogenic Cardiomyopathy Compared With Arrhythmogenic Right Ventricular Cardiomyopathy. JACC Cardiovascular Imaging. ISSN 1936-878X. 18(8), p. 853–863. doi: 10.1016/j.jcmg.2025.03.018. Full text in Research Archive Show summary

  Background Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inheritable heart disease, whereas exercise-induced arrhythmogenic cardiomyopathy (EiAC) is a proposed acquired similar phenotype in athletes. The differences in disease progression between these entities are not well understood. Objectives This study aims to assess structural, functional, and arrhythmic disease progression in EiAC compared with ARVC. Methods This longitudinal cohort study included EiAC patients who were competitive endurance athletes (>24 MET-hours/week for >6 consecutive years) referred due to ventricular arrhythmias (VA), without inherited or genetic factors or other evident causes, and genotype-positive ARVC patients with a definite diagnosis and their genotype-positive family members for comparison. Disease progression was assessed by repeated echocardiographic examinations and incident VA during long-term follow-up. Results The authors included 125 ARVC patients (61 women, aged 38 ± 17 years) and 41 EiAC patients (6 women, aged 45 ± 13 years) and followed them for 96 months (Q1-Q3: 73-132 months) and 82 months (Q1-Q3: 50-118 months), respectively. The authors analyzed 730 echocardiographic examinations (538 ARVC, 192 EiAC). Right ventricular (RV) structure and function remained stable in EiAC patients, whereas those in ARVC patients deteriorated during follow-up. The 5-year and 10-year cumulative incidences of VA were similar between EiAC and ARVC patients. Conclusions RV structure and function deteriorated in ARVC patients but remained stable in EiAC patients during follow-up. The incidence of VA was high in both populations. These results indicate that EiAC patients should be followed closely over time regardless of structural and functional progression.

• Bortoli, Alessandro De; Nordøy, Ingvild; Connelly, James Pattrick; Viermyr, Hans-Kittil; Bjerkreim, Randi Haukaas & Broch, Kaspar [Show all 15 contributors for this article] (2024). Diagnostics, treatment and outcomes of cardiac sarcoidosis in a Norwegian cohort. International Journal of Cardiology. ISSN 0167-5273. 400. doi: 10.1016/j.ijcard.2024.131809. Full text in Research Archive Show summary

  Background Evidence-based guidelines for cardiac sarcoidosis (CS) regarding use of second- and third-line agents, treatment duration, surveillance and prognostic factors are lacking. Objective To analyze the clinical presentation, diagnostics, treatment, monitoring and clinical outcomes in a Norwegian cohort. Methods Using discharge diagnoses between 2017 through 2020 from a large tertiary center, we identified 52 patients with CS. We performed a systematic chart review following a pre-specified checklist. The primary outcome of major cardiovascular events (MACE) was defined as a composite of cardiovascular hospitalization, defibrillator therapy, cardiac transplantation, or death. Results 18-fluorodeoxyglucose positron emission tomography (FDG-PET) showed pathological tracer uptake in 35/36 (97%) of immunosuppression-naïve patients. Immunosuppressive treatment was administered to 49/52 patients (94%) for a median of 43 (IQR 34) months; 69% were treated with second-line (methotrexate, azathioprine, mycophenolate mofetil) and 25% with third-line (rituximab, infliximab) agents, respectively. Rituximab reduced inflammation as assessed by interval FDG-PET imaging and was overall well tolerated. Median duration to first MACE was 6 (IQR 10) months and 17/23 patients (74%) experienced a MACE within 12 months from CS diagnosis. No mortality was recorded and 20% achieved full remission. Age below the median of 53 years at time of diagnosis was associated with an increased risk of a MACE. Conclusion Long-term immunosuppression including a liberal use of non-steroidal agents, appeared essential in treating CS. Although the burden of cardiovascular events was substantial, the survival was excellent in this contemporary cohort. Prospective randomized studies are urgently needed to define the best therapy for these patients.

• Olsen, Paul Anders S.; Fossmark, Reidar & Qvigstad, Gunnar (2015). Fecal calprotectin in patients with suspected small bowel disease – a selection tool for small bowel capsule endoscopy? Scandinavian Journal of Gastroenterology. ISSN 0036-5521. 50(3), p. 272–277. doi: 10.3109/00365521.2014.1003395. Full text in Research Archive

View all works in NVA

• Olsen, Paul Anders Sletten & Beitnes, Jan Otto (2024). Klinisk ekkokardiografi. Universitetsforlaget. Full text in Research Archive

View all works in NVA

• Olsen, Paul Anders Sletten; Leren, Ida Skrinde; Lie, Øyvind Haugen; Bugge, Cecilie; Beitnes, Jan Otto & Berge, Knut Erik [Show all 8 contributors for this article] (2026). Cardiac function and the effect of heart failure treatment in patients with genotype-positive dilated cardiomyopathy. Full text in Research Archive
• Apostu, Alexandra; Olsen, Paul Anders Sletten; Bugge, Cecilie; Ionescu, Bogdana; Jurcut, Ruxandra & Haugaa, Kristina Ingrid Helena Hermann (2026). Refining Risk Stratification for Ventricular Arrhythmias in Patients with Desmoplakin Cardiomyopathy. Full text in Research Archive
• Olsen, Paul Anders Sletten (2025). Isbading: Populær trend uten vitenskapelig bevis for helsefordeler. [Internet]. faktisk.no. Full text in Research Archive Show summary

  Isbading har blitt en populær aktivitet, men forskningen mangler solide bevis for varige helsefordeler. Les mer om debatten rundt isbadingens effekt på helse.

• Olsen, Paul Anders S.; Quist-Paulsen, Petter; Brudevold, Robert; Ogarkov, Aleksei & Brenna, Øystein (2018). En kvinne med residiverende feber, tørrhoste og ascites. Tidsskrift for Den norske legeforening (Tidsskriftet). ISSN 0029-2001. 138(10). doi: 10.4045/tidsskr.17.0817. Full text in Research Archive

View all works in NVA